Janus Henderson Global Life Sciences Fund
Janus Investment Fund · 7 share classes
Fund classification
Classified from what the fund holds · as of 2026 Q2
Janus Henderson Global Life Sciences Fund is an actively managed U.S. equity fund.
- Asset class
- Equity
- Region
- United States
- Management
- Actively managed
- Fund type
- Open-end fund
Fund profile
As filed in the prospectus · 2026 Q1
Janus Henderson Global Life Sciences Fund seeks long-term growth of capital.
The fund invests primarily in equity securities of U.S. and foreign companies in the life sciences sector—including pharmaceuticals, biotechnology, health care services, medical devices, agriculture, and cosmetics—selected through bottom-up analysis for growth potential, management quality, competitive advantages, and returns on capital. Portfolio management incorporates environmental, social, and governance factors alongside fundamental analysis and applies screens to avoid UN Global Compact violators and to hold at least 80% of assets in issuers with an MSCI ESG rating of BB or higher. Because security selection depends on portfolio management's assessment of individual companies, fund performance may diverge from that of life sciences equity benchmarks.
| Share class | Expense ratio |
|---|---|
| JAGLX | 0.92% |
| JFNAX | 1.00% |
| JFNCX | 1.79% |
| JFNIX | 0.78% |
| JFNSX | 1.19% |
| JNGLX | 0.81% |
| JFNNX | 0.68% |
Portfolio turnover 30.00% · as of 2026 Q1
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 99.11% |
| Cash & short-term | 0.90% |
| Other | 0.01% |
Derivatives are shown at market value, not notional exposure.
Sector allocation
The same holdings as Allocation above, grouped by market sector instead of asset type · as of 2026 Q2
| Health Care | 82.6% |
| International | 15.7% |
| Cash | 0.9% |
| Other | 0.9% |
Government, Securitized and Cash are non-corporate buckets; International is foreign holdings we don’t sector-classify, and Other is the residual (held funds, unresolved names).
Latest quarter
What changed since the fund's previous filing
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
| Share class | 1-year | 3-year | 5-year | Vol | Worst fall |
|---|---|---|---|---|---|
| +21.39% | +33.62% | +39.78% | 16.81% | -17.73% | |
| +21.28% | +33.25% | +39.16% | 16.80% | -17.78% | |
| +20.42% | +30.33% | +34.21% | 16.79% | -18.23% | |
| +21.54% | +34.12% | +40.71% | 16.81% | -17.65% | |
| +21.04% | +32.53% | +37.86% | 16.81% | -17.91% | |
| +21.52% | +34.00% | +40.46% | 16.80% | -17.67% | |
| +21.64% | +34.51% | +41.40% | 16.81% | -17.60% |
These classes hold the same portfolio, so the 7.18pp spread over 5 years is the cost difference between them — roughly 1.44pp a year — not a difference in what they own.
May 2026 and Jun 2026 have been filed since the trailing figures were struck, so they are not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| LLY | Eli Lilly & Co.LLY | 9.41% | $1,199.43 | $546.44M | 455.6K |
| JNJ | Johnson & JohnsonJNJ | 7.09% | $253.97 | $411.81M | 1.6M |
| ABBV | AbbVie, Inc.ABBV | 4.67% | $251.64 | $271.02M | 1.1M |
| UNH | UnitedHealth Group, Inc.UNH | 4.54% | $415.63 | $263.63M | 634.3K |
| — | AstraZeneca plc | 3.93% | $187.11 | $228.27M | 1.2M |
| RVMD | Revolution Medicines, Inc.RVMD | 3.02% | $187.28 | $175.40M | 936.6K |
| ARGX | Argenx SEARGX | 2.63% | $927.77 | $152.70M | 164.6K |
| NVS | Novartis AGNVS | 2.56% | $156.72 | $148.84M | 949.7K |
| TMO | Thermo Fisher Scientific, Inc.TMO | 2.33% | $501.36 | $135.41M | 270.1K |
| PRAX | Praxis Precision Medicines, Inc.PRAX | 2.19% | $334.79 | $127.00M | 379.4K |
Reported price is the fund's own reported value divided by its own reported shares at 2026-06-30 — not a live quote, and not what the fund paid.
Top 10 positions are 42.37% of net assets, top 25 67.94%, across 103 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free